Bedrijfsoverzicht
China SXT Pharmaceuticals, Inc. is a specialized pharmaceutical entity focused on the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) within the Chinese market. The company's product portfolio encompasses advanced, fine, and regular TCMP products, alongside raw medicinal materials such as SanQiFen and HongQi. Operating within the Healthcare sector and specifically the Drug Manufacturers - Specialty & Generic industry, the firm leverages traditional medical knowledge combined with modern manufacturing capabilities to serve a niche therapeutic segment. In terms of corporate scale, the company reports a market capitalization of $1.98M and employs a workforce of 75 individuals. The annual revenue for the trailing twelve months stands at $1.54M, figures that indicate a small-cap status with limited revenue generation relative to larger pharmaceutical peers. This modest market cap suggests the company operates as a micro-cap entity, where valuation metrics are often driven by specific asset values or pipeline potential rather than broad revenue multiples. The combination of a low market cap and a small employee base highlights a highly concentrated operational structure typical of early-stage or niche-focused biotech and pharmaceutical firms.
Financiële gezondheid
The financial performance for the trailing twelve months reflects a challenging operational environment, with revenue totaling $1.54M while net income reported a loss of $-8,869,886 and EBITDA reaching $-8,335,278. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure characterized by high operating expenses that far exceed the gross revenue generated, a common scenario in research and development intensive phases. Free cash flow stands at $-1,948,357, indicating that the company is burning cash at a rate that exceeds its operational cash generation, which limits immediate financial flexibility without external capital infusion. Despite these operational losses, the company maintains a cash reserve of $21.31M, which provides a buffer against the current burn rate, though the debt obligation of $1.20M must also be managed within this liquidity pool. The debt-to-equity ratio is recorded at 5.95, suggesting a highly leveraged balance sheet where equity is minimal relative to the debt load, though the absolute debt amount remains low. The current ratio is 4.37, a metric that indicates strong short-term liquidity as current assets significantly outweigh current liabilities, providing ample coverage for immediate obligations. Return on Equity is -50.3% and Return on Assets is -18.3%, metrics that collectively reveal that management is currently destroying shareholder and asset value rather than generating returns, a typical characteristic of firms in deep development or restructuring phases.
Waarderingsbeoordeling
Valuation multiples for China SXT Pharmaceuticals, Inc. are presented with significant constraints due to its financial performance, as the trailing P/E ratio is N/A and the forward P/E is also N/A. The absence of a trailing P/E and forward P/E implies that the market cannot value the stock based on current or expected earnings per share, necessitating a reliance on asset-based or revenue-based valuation methods instead. The price-to-book ratio is 0.09, a figure that indicates the stock is trading at a deep discount to its book value, suggesting the market perceives the asset base as impaired or that the company's future cash flow potential is severely discounted. Alternative valuation metrics provide further insight, with a price-to-sales ratio of 1.29 and an EV/EBITDA of 2.20, which suggest the company is valued based on its sales scale and enterprise value relative to earnings before interest, taxes, depreciation, and amortization, despite the negative earnings. The 52-week high is $1047.00 and the 52-week low is $1.25, meaning the current trading price sits at 1.25% above the 52-week low and significantly below the 52-week high. The beta value is 1.75, a statistic that indicates the stock's price volatility is substantially higher than the broader market, moving 75% more than the market index on average during periods of fluctuation.
Growth & Income
Revenue growth year-over-year is -24.5%, while earnings growth is N/A due to the absence of positive earnings in the prior period for comparison. The negative revenue growth rate indicates a contraction in sales, which implies that the company is facing headwinds in its domestic market or is scaling down operations. Since the company reports a net loss, it is technically not paying dividends, resulting in a dividend yield of N/A and a payout ratio of 0.0%, meaning the company retains all its scarce cash rather than distributing it to shareholders. This reinvestment strategy, or lack thereof due to cash constraints, suggests that capital is being directed toward sustaining operations or R&D rather than providing income to investors. The overall growth and income profile for China SXT Pharmaceuticals, Inc. is defined by revenue contraction, negative returns, and a complete absence of dividend distributions, painting a picture of a distressed small-cap entity requiring significant capital preservation.